Shots:
- Orion & Criceto have entered into an exclusive license agreement to develop & commercialize Aporon for the treatment of OFF episodes in pts with Parkinson’s disease
- As per the deal, Orion will obtain global exclusive license of Aporon excl. the US & Canada in exchange for upfront payments, reimbursements for development costs & sales-based royalties
- Aporon is an apomorphine oromucosal spray which is being evaluated in a Criceto-led P-III trial as the 1L treatment of OFF episodes in Parkinson’s disease
Ref: GlobeNewswire| Image: Orion & Criceto
Related News:- Marinus Pharmaceuticals Highlights the P-III (RAISE) Study Data of Ganaxolone to Treat Refractory Status Epilepticus (RSE) at NCS 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
